612 related articles for article (PubMed ID: 29207939)
1. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
Stroud CR; Hegde A; Cherry C; Naqash AR; Sharma N; Addepalli S; Cherukuri S; Parent T; Hardin J; Walker P
J Oncol Pharm Pract; 2019 Apr; 25(3):551-557. PubMed ID: 29207939
[TBL] [Abstract][Full Text] [Related]
2. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
3. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.
Horisberger A; La Rosa S; Zurcher JP; Zimmermann S; Spertini F; Coukos G; Obeid M
J Immunother Cancer; 2018 Dec; 6(1):156. PubMed ID: 30587227
[TBL] [Abstract][Full Text] [Related]
4. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.
Wijn DH; Groeneveld GH; Vollaard AM; Muller M; Wallinga J; Gelderblom H; Smit EF
Eur J Cancer; 2018 Nov; 104():182-187. PubMed ID: 30368069
[TBL] [Abstract][Full Text] [Related]
5. Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy.
Shafqat H; Gourdin T; Sion A
Semin Oncol; 2018 Jun; 45(3):156-163. PubMed ID: 30348532
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M
Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270
[TBL] [Abstract][Full Text] [Related]
7. Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
Mouri A; Kaira K; Yamaguchi O; Shiono A; Miura Y; Hashimoto K; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
Cancer Chemother Pharmacol; 2019 Oct; 84(4):873-880. PubMed ID: 31444618
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
Dimitriou F; Hogan S; Menzies AM; Dummer R; Long GV
Eur J Cancer; 2021 Nov; 157():214-224. PubMed ID: 34536945
[TBL] [Abstract][Full Text] [Related]
9. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
10. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
11. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
12. Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.
Ornstein MC; Calabrese C; Wood LS; Kirchner E; Profusek P; Allman KD; Martin A; Kontzias A; Grivas P; Garcia JA; Calabrese LH; Rini BI
Clin Genitourin Cancer; 2019 Jun; 17(3):177-182. PubMed ID: 30824360
[TBL] [Abstract][Full Text] [Related]
13. Predictors of immunotherapy-induced immune-related adverse events.
Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
[TBL] [Abstract][Full Text] [Related]
14. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
[TBL] [Abstract][Full Text] [Related]
15. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.
Mekki A; Dercle L; Lichtenstein P; Marabelle A; Michot JM; Lambotte O; Le Pavec J; De Martin E; Balleyguier C; Champiat S; Ammari S
Eur J Cancer; 2018 Jun; 96():91-104. PubMed ID: 29698933
[TBL] [Abstract][Full Text] [Related]
16. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
[TBL] [Abstract][Full Text] [Related]
17. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
18. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
Bergqvist V; Hertervig E; Gedeon P; Kopljar M; Griph H; Kinhult S; Carneiro A; Marsal J
Cancer Immunol Immunother; 2017 May; 66(5):581-592. PubMed ID: 28204866
[TBL] [Abstract][Full Text] [Related]
19. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.
Alessandrino F; Sahu S; Nishino M; Adeni AE; Tirumani SH; Shinagare AB; Awad MM
Abdom Radiol (NY); 2019 May; 44(5):1917-1927. PubMed ID: 30790009
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
